HIV-1非核苷类反转录酶抑制剂耐药相关突变及其复制适应性研究

HIV-1 non-nuclaoside reverse transcriptase inhibitors resistance-associated mutations and viral fitness

非核苷类反转录酶抑制剂是高效抗反转录病毒疗法(HAART)治疗艾滋病的重要组成部分。文章综述了非核苷类反转录酶抑制剂(NNRTIs)的耐药相关突变位点,如主要耐药突变位点、罕见的耐药突变位点、非多态性附属耐药突变位点及突变位点的相互作用;并分别阐述了各个主要耐药突变位点对病毒复制适应性的影响。对今后HIV-1NNRTIs耐药相关工作进行了展望。

The first-generation non-nuclaoside reverse transcriptase inhibitors （NNRTIs） including Nevirapine （NVP） and Efavirenz （EFV） are the important components of first-line highly active antiretroviral therapy （HAART） for AIDS patients. This review focuses on NNRTIs resistance-associated mutations including major drug-resistance mutations, highly unusual mutations, non polymorphism accessory mutations and their interactions with each other. The effect of each major drug-resistance mutation on viral fitness is described respectively. The work associated with human immunodeficiency virus I（HIV 1） NNRTIs drug resistance is prospected.